Conversion of peripheral blood mononuclear cells into tumor-specific cytolytic cell populations using tumor cells engineered with multiple immunomodulatory factors

Conclusions: 

These findings indicate that human tumor cell lines that express multiple immunostimulatory can induce potent tumor killing immune cell populations with broad tumor cell reactivity but no detectable killing of allogeneic PBMCs This strategy is being developed for clinical use as an autologous adoptive immunotherapy for cancers.

We report that: 

1.  ENLIST cell stimulated and differentiated hPBMCs develop into tumor killing populations with potent activity against multiple types of tumor cells.
2.  ENLIST differentiated hPBMCs do not kill autologous or allogeneic PBMC, which suggests that they will not kill normal/non tumor cells.
3.  CyTOF analysis provides a clear picture of the immune effector cell types that arise in these ENLIST cell differentiation cultures These cells also acquire increased expression of functional effector factors such as Granzymes and Perforin.